Scorpion Therapeutics Receives BioSpace NextGen Bio “Class of 2022” Recognition
BOSTON--(BUSINESS WIRE)-- Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, has been selected by BioSpace to join its NextGen Bio “Class of 2022.” The recognition from BioSpace, a life sciences industry news outlet and career hub, highlights top up-and-coming biopharmaceutical companies to watch in the new year.
“We are pleased to be a part of BioSpace’s NextGen Bio ‘Class of 2022’ and to join an esteemed list of companies being recognized for their potential to advance the biotech industry,” said Axel Hoos, M.D., Ph.D., CEO of Scorpion. “This recognition for Scorpion reflects the team’s efforts to extend the frontiers of oncology research and patient care through our Precision Oncology 2.0 strategy.”
For the past eight years, BioSpace NextGen Bio has honored the most innovative new biopharmaceutical companies from across the United States. Scorpion is one of 30 companies in the “Class of 2022” that was recognized based on a number of factors, including funding, collaborations, pipeline, growth potential and innovation.
For more information, read BioSpace’s article on this year’s recipients.
About Scorpion Therapeutics
Scorpion Therapeutics is a pioneering oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion refers to as Precision Oncology 2.0. Scorpion has built a proprietary and fully integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, that enables it to consistently and rapidly create exquisitely selective small molecule compounds against an unprecedented spectrum of targets. Scorpion aims to leverage its platform to advance a broad pipeline of wholly owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets. For more information, visit www.scorpiontx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005716/en/
Source: Scorpion Therapeutics
View this news release online at: